[Skip to Content]
[Skip to Content Landing]
Views 67
Citations 0
Comment & Response
December 13, 2018

Inappropriate Grading of Adverse Events in Cancer Clinical Trials

Author Affiliations
  • 1Fudan University Shanghai Cancer Center, Shanghai, China
  • 2Rizhao City Hospital of Traditional Chinese Medicine, Rizhao, China
JAMA Oncol. Published online December 13, 2018. doi:10.1001/jamaoncol.2018.5849

Consideration of toxic effects is a critical part of cancer treatment. Therefore, the grading and reporting of all grades of adverse events, especially high-grade adverse events, must be standardized to allow for consistency and comparison across trials. The Common Terminology Criteria for Adverse Events (CTCAE) has been widely used for reporting of adverse events in oncology journals and at meetings.1